Assessing dalfampridine efficacy in the physician's office.

Abstract

Dalfampridine (extended release 4-aminopyridine) is shown in three recent randomised controlled trials to improve walking speed in people with multiple sclerosis; however, the trial literature makes it clear that dalfampridine is effective in only a subset of patients. For the neurologist working in an everyday physician's office, a key question arises: How to distinguish the few who experience a meaningful clinical benefit, from the many who do not? This question has not yet been adequately addressed in the available literature.

• Authors: J B Raffel, O Malik, R S Nicholas
• Journal: Multiple sclerosis (Houndmills, Basingstoke, England) (Mult Scler) Vol. 20 Issue 1 Pg. 24-6 (Jan 2014) ISSN: 1477-0970 [Electronic] England
• PMID: 23727943 (Publication Type: Journal Article)

Chemical References

• Potassium Channel Blockers
• 4-Aminopyridine

Topics

• 4-Aminopyridine (therapeutic use)
• Humans
• Mobility Limitation
• Multiple Sclerosis (complications, drug therapy)
• Physicians' Offices
• Potassium Channel Blockers (therapeutic use)
• Treatment Outcome
• Walking